Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 5,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Infection Clear all

Conditions: Sexually Transmitted Infections
Interventions: STI/HIV Intervention Behavioral Intervention Program; Behavioral
Lead sponsor: Madigan Army Medical Center; Federal
Eligibility: 18 Years to 30 Years
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Fayetteville, North Carolina • Tacoma, Washington

Conditions: HIV
Interventions: MRI, L-NMMA, Acetylcholine; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Nephrolithiasis, Urosepsis
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Influenza Infection
Interventions: VRC-FLUNPF099-00-VP (H1ssF_3928); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Skin Diseases, Infectious, Staphylococcal Skin Infections
Interventions: Ceftaroline, Vancomycin; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Detroit, Michigan

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Nelfinavir mesylate, Efavirenz, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 6 more

Conditions: Healthy
Interventions: Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant, Placebo, gp140 HIV Bivalent Vaccine; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 11
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more

Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Interventions: Methotrexate, Leucovorin calcium, Zidovudine, Dexamethasone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Bacterial Vaginosis, Vaginal Flora Imbalance
Interventions: Flourish Vaginal Care System; Combination Product
Lead sponsor: Vaginal Biome Science; Other
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Concord, New Hampshire

Conditions: Respiratory Viral Infection
Interventions: zinc-green tea extract-ascorbic acid, Placebo; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 22
States / cities: San Diego, California • San Francisco, California • San Mateo, California + 14 more

Conditions: Cytomegalovirus Infection
Interventions: Valganciclovir; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Rhinovirus
Interventions: Nasal Swab Healthy Surveillance, Nasal Swab Sick Samples, Nasal Swab Hospitalized Cohort, Sick Follow-up Survey, Older Cohort Control Group, Procedural Comfort or Care; Diagnostic Test · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Up to 17 Years
Enrollment: 670 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acute Respiratory Infection
Interventions: Integrated clinical prediction rule (iCPR) system (iCPR); Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: New York, New York • Salt Lake City, Utah • Madison, Wisconsin

Conditions: Genital Herpes, HSV-2 Infection
Interventions: GEN-003, Matrix-M2, 0.9% normal saline; Biological · Other
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: Not listed
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 8
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more

Conditions: Sterile Catheter, Catheter-related Bloodstream Infections, Dialysis Catheter, Dialysis
Interventions: Catheter Caps Case (C3); Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Uveitis, Cystoid Macular Edema
Interventions: Pegaptanib; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: HIV Infections
Interventions: Infección de Amor (Infectious Love); Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy Volunteers, Rhinovirus
Interventions: RG-HRV16; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Chronic Hepatitis C
Interventions: SOF, RBV, Placebo to match SOF, Placebo to match RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 50
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 40 more

Conditions: Lymphoma, Nonneoplastic Condition
Interventions: polymerase chain reaction, laboratory biomarker analysis; Genetic · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 11 more

Conditions: Periprosthetic Infection Total Hip Arthoplasty
Interventions: open debridement with modular exchange, one stage exchange; Procedure
Lead sponsor: OrthoCarolina Research Institute, Inc.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Cesarean Section, Infection
Interventions: Cefazolin (Timing of Antibiotic Prophylaxis); Drug
Lead sponsor: MemorialCare; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Long Beach, California • Orange, California

Conditions: Shoulder Arthropathy Associated With Other Conditions, Shoulder Arthritis, Shoulder Osteoarthritis, Shoulder Pain
Interventions: Jumpstart Dressing, Standard Dressing; Device · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

STI/HIV Intervention Behavioral Intervention Program

Sildenafil to Treat HIV-Associated Pulmonary Hypertension

Serum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy.

Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA

Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer

Clinical Trial to Survey Results of Flourish Vaginal Care System for Recurrent Bacterial Vaginosis

Zinc and Green Tea Extract for Community Respiratory Viral Infections

A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

Study of Prophylactic Vs Preemptive Valganciclovir

The Rhinovirus Hospitalization and Investigation of Nasal-airway Omics (RHINO) Study

Decreasing Antibiotic Prescribing in Acute Respiratory Infections Through Nurse Driven Clinical Decision Support

Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

Dialysis Catheter Caps Case Feasibility Study

Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema

Impact of a Telenovela/Soap Opera for HIV Prevention in Latinas

Study of Airway Inflammatory Responses to Experimental Rhinovirus Infection

Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon

Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma

Treatment of Acute Periprosthetic Total Hip Arthroplasty Infections

Trial Comparing the Optimal Timing of Antibiotic Prophylaxis at the Time of Cesarean Delivery

Microcurrent Dressing to Treat Infections, Before, During and After Surgery